Global Myasthenia Gravis Market to Reach US$2.89 Billion by 2030, Driven by Immunotherapies and Biologic Advancements
Myasthenia gravis (MG) is a chronic, progressive, and uncommon neuromuscular disorder. In this autoimmune disorder in which the head, limb, spinal, ocular, and respiratory muscles …